Showing results (251-260 of 283) with videos related to

Sort By:
Pageof 29
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 1998
Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: a prospective randomized study of 300 patientsW P Steward, J von Pawel, U Gatzemeier, et al.
British Journal of Cancer|July 17, 1999
Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancerN Thatcher, E S De Campos, D R Bell, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 21, 2013
Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial)S Ramalingam, J Crawford, A Chang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 30, 2012
Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumorsV M Macaulay, M R Middleton, A S Protheroe, et al.
The British Journal of Dermatology|July 17, 2013
Treatment patterns, outcomes, and resource utilization of patients with metastatic melanoma in the U.K.: the MELODY studyP Lorigan, M Marples, M Harries, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 25, 2010
The influence of sex and histology on outcomes in non-small-cell lung cancer: a pooled analysis of five randomized trialsP Wheatley-Price, F Blackhall, S-M Lee, et al.
British Journal of Cancer|May 19, 2011
Continuous low-dose cyclophosphamide and methotrexate combined with celecoxib for patients with advanced cancerO A Khan, A D Blann, M J Payne, et al.
British Journal of Cancer|September 29, 2005
The safety and feasibility of extracorporeal high-intensity focused ultrasound (HIFU) for the treatment of liver and kidney tumours in a Western populationR O Illing, J E Kennedy, F Wu, et al.
Cancer Immunology, Immunotherapy : CII|May 21, 2022
Treatment with a retinoic acid-inducible gene I (RIG-I) agonist as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: results from two phase 1 studiesV Moreno, E Calvo, M R Middleton, et al.
The British Journal of Radiology|June 19, 2008
High-intensity focused ultrasound ablation of liver tumours: can radiological assessment predict the histological response?T A Leslie, J E Kennedy, R O Illing, et al.
Pageof 29